Banning AP, Baumbach A, Blackman D Percutaneous coronary intervention in the UK: recommendations for good practice 2015. Heart. 2015; 101:(Suppl 3)1-13

Bonaca MP, Bhatt DL, Cohen M Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372:(19)1791-1800

Feres F, Costa RA, Abizaid A Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310:(23)2510-2522

Kim HS, Kang J, Hwang D Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020; 396:(10257)1079-1089

Mauri L, Kereiakes DJ, Yeh RW Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine. 2014; 371:(23)2155-2166

Pottle A, Deane S, Dent N How effective is a nurse-led follow-up clinic for patients post Percutaneous Coronary Intervention (PCI)?. European Heart Journal. 2013; 34:5923-5923

Safley DM, Amin AP, House JA Comparison of costs between transradial and transfemoral percutaneous coronary intervention: a cohort analysis from the Premier research database. Am Heart J. 2013; 165:(3)303-9.e2

Valgimigli M, Costa F, Byrne R, Haude M, Baumbach A, Windecker S. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention. 2015; 11:(1)68-74

Witberg G, Zusman O, Yahav D, Perl L, Vaknin-Assa H, Kornowski R. Meta-analysis of studies examining the external validity of the dual antiplatelet therapy score. Eur Heart J Cardiovasc Pharmacother. 2020; 6:(5)285-291

Personalisation of DAPT: from ‘bench’ to bedside

02 January 2022
Volume 4 · Issue 1


The ideal duration of antiplatelet therapy following percutaneous coronary intervention is a topic of much discussion within the cardiology community. Numerous contemporary studies have highlighted benefits of both shortened and prolonged treatment courses within particular patient cohorts. Despite this, there is a delay in seeing such individualised decisions being made within stretched healthcare systems. We aimed to highlight this issue and facilitate discussions on how we can bring this important research from ‘bench’ to ‘bedside’.

The duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is a constantly evolving field. Trials have demonstrated non-inferiority for early de-escalation of DAPT therapy (Feres et al, 2013; Kim et al, 2020) with reduced bleeding, conversely, studies examining extended therapy have shown reduced major adverse cardiovascular events (MACE), and have thus generated much interest within the cardiology community (Bonaca et al, 2015; Mauri et al, 2014). It is evident that a personalised approach to antiplatelet choice and duration can improve patient outcomes.

Scoring systems, such as the DAPT score, have been developed to aid clinicians in risk stratification post PCI, and subsequently in DAPT duration decisions al, 2020). A recent meta-analysis demonstrated that a DAPT score >2 was associated with a higher risk of MACE; with an extended course of treatment (18-24 months) being associated with reduced risk in this cohort when compared to a 12-month duration (Witberg et al, 2020).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month